Endo Targets Opana ER Abuse-Deterrent Filing In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo continues to believe it can rebuild Opana ER, despite generic competition, by adding abuse-deterrent labeling and securing critical intellectual property protection.
You may also be interested in...
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
No Abuse-Resistance Claim For Endo’s Opana ER Reformulation
Endo’s Opana ER reformulation, which uses proprietary technology to deter crushing, receives approval but no labeling language on crush-resistance or abuse deterrence, according to FDA. The company says a U.S. patent to be issued Dec. 13 will protect the new formulation until November 2023.
What Seagen’s Pipeline Will Bring To Pfizer
Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.